YONKERS, NY--(Marketwire - April 01, 2008) - Advanced Viral Research Corp. (OTCBB: ADVR) announced today that enrollment for its Phase II efficacy study for AVR118 in cancer cachexia is progressing in line with expectations.
YONKERS, NY--(Marketwire - April 01, 2008) - Advanced Viral Research Corp. (OTCBB: ADVR) announced today that enrollment for its Phase II efficacy study for AVR118 in cancer cachexia is progressing in line with expectations.